184 related articles for article (PubMed ID: 21807052)
1. Safety and immunogenicity of a candidate parvovirus B19 vaccine.
Bernstein DI; El Sahly HM; Keitel WA; Wolff M; Simone G; Segawa C; Wong S; Shelly D; Young NS; Dempsey W
Vaccine; 2011 Oct; 29(43):7357-63. PubMed ID: 21807052
[TBL] [Abstract][Full Text] [Related]
2. Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.
Penkert RR; Young NS; Surman SL; Sealy RE; Rosch J; Dormitzer PR; Settembre EC; Chandramouli S; Wong S; Hankins JS; Hurwitz JL
Vaccine; 2017 Jun; 35(29):3615-3620. PubMed ID: 28554503
[TBL] [Abstract][Full Text] [Related]
3. Generation of a parvovirus B19 vaccine candidate.
Chandramouli S; Medina-Selby A; Coit D; Schaefer M; Spencer T; Brito LA; Zhang P; Otten G; Mandl CW; Mason PW; Dormitzer PR; Settembre EC
Vaccine; 2013 Aug; 31(37):3872-8. PubMed ID: 23827313
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
Ballou WR; Reed JL; Noble W; Young NS; Koenig S
J Infect Dis; 2003 Feb; 187(4):675-8. PubMed ID: 12599085
[TBL] [Abstract][Full Text] [Related]
6. Candidate recombinant vaccine for human B19 parvovirus.
Bansal GP; Hatfield JA; Dunn FE; Kramer AA; Brady F; Riggin CH; Collett MS; Yoshimoto K; Kajigaya S; Young NS
J Infect Dis; 1993 May; 167(5):1034-44. PubMed ID: 8486937
[TBL] [Abstract][Full Text] [Related]
7. T-helper cell-mediated interferon-gamma, interleukin-10 and proliferation responses to a candidate recombinant vaccine for human parvovirus B19.
Franssila R; Hedman K
Vaccine; 2004 Sep; 22(27-28):3809-15. PubMed ID: 15315862
[TBL] [Abstract][Full Text] [Related]
8. Erythematous exanthem associated with primary infection by human parvovirus B19.
Veraldi S; Rizzitelli G
Int J Dermatol; 1995 Feb; 34(2):119. PubMed ID: 7737770
[No Abstract] [Full Text] [Related]
9. Recombinant Virus-like Particles of Human Parvovirus B19 with the Internal Location of VP1 Unique Region Produced by
Shao S; Wang Q; Jin Y; Zhang X; Liu Z; Chen S; Wu H; Yang S; Tang F; Su J; Liang Y; Zhang J; Li Q
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366508
[TBL] [Abstract][Full Text] [Related]
10. B19 parvovirus.
Young NS
Baillieres Clin Haematol; 1995 Mar; 8(1):25-56. PubMed ID: 7663050
[TBL] [Abstract][Full Text] [Related]
11. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.
Gigler A; Dorsch S; Hemauer A; Williams C; Kim S; Young NS; Zolla-Pazner S; Wolf H; Gorny MK; Modrow S
J Virol; 1999 Mar; 73(3):1974-9. PubMed ID: 9971777
[TBL] [Abstract][Full Text] [Related]
12. Symptoms associated with parvovirus B19 infection in adults: a pilot study.
Waza K; Inoue K; Matsumura S
Intern Med; 2007; 46(24):1975-8. PubMed ID: 18084119
[TBL] [Abstract][Full Text] [Related]
13. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
14. Parvovirus B19 infection.
Kerr JR
Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):10-29. PubMed ID: 8641299
[TBL] [Abstract][Full Text] [Related]
15. Prolonged parvovirus b19 viremia in spite of neutralizing antibodies after erythema infectiosum in pregnancy.
Dobec M; Juchler A; Flaviano A; Kaeppeli F
Gynecol Obstet Invest; 2007; 63(1):53-4. PubMed ID: 16940737
[TBL] [Abstract][Full Text] [Related]
16. [Observations on human parvovirus B19 infection diagnosed in 2011].
Mihály I; Trethon A; Arányi Z; Lukács A; Kolozsi T; Prinz G; Marosi A; Lovas N; Dobner IS; Prinz G; Szalai Z; Pék T
Orv Hetil; 2012 Dec; 153(49):1948-57. PubMed ID: 23204301
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses in parvovirus B19 infected patients.
Modrow S; Dorsch S
Pathol Biol (Paris); 2002 Jun; 50(5):326-31. PubMed ID: 12116851
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Demonstration of Parvovirus B19 Viral Protein 2 in Periflexural Exanthema in an Adult, Supporting Antibody-Dependent Enhancement as Means of Endothelial Uptake of the Virus.
Santonja C; Pielasinski Ú; Polo J; Kutzner H; Requena L
Am J Dermatopathol; 2018 Feb; 40(2):e19-e24. PubMed ID: 28700372
[TBL] [Abstract][Full Text] [Related]
20. Raynaud's phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes.
Harel L; Straussberg R; Rudich H; Cohen AH; Amir J
Clin Infect Dis; 2000 Mar; 30(3):500-3. PubMed ID: 10722434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
